ASXL1 and myeloid neoplasm: ASXL1 loss or mutation impairs the recruitment of PRC2 complex proteins to chromatin, reducing H3K27me3 deposition, and leading to associated leukemogenic gene dysregulation and the development of myeloid malignancies (16–18, 22, 48).